Analysis & Expressing Resultd in Clinical Trials Dr. Khalili.

Slides:



Advertisements
Similar presentations
CQ Deng, PhD PPD Development Research Triangle Park, NC 27560
Advertisements

Appraisal of an RCT using a critical appraisal checklist
The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Short introduction An example of the use of survival analysis.
Systematic Review of Literature Part XIX Analyzing and Presenting Results.
1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.
Design & Interpretation of Randomized Trials: A Clinician’s Perspective Francis KL Chan Department of Medicine & Therapeutics CUHK.
Design and Analysis of Clinical Study 12. Randomized Clinical Trials Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
Meta Analyses and Systematic Reviews HINF Medical Methodologies Session 12.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Clinical Trials Hanyan Yang
TREATMENT 2 Evaluation of interventions Types of RCT Blinding.
EPIDEMIOLOGY Why is it so damn confusing?. Disease or Outcome Exposure ab cd n.
1 Efficacy Results NDA (MTP-PE) Laura Lu Statistical Reviewer Office of Biostatistics FDA/CDER.
Advanced Statistics for Interventional Cardiologists.
Introduction to Clinical Trials
The Diabetic Retinopathy Clinical Research Network 5-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for.
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
Sample Size Determination Donna McClish. Issues in sample size determination Sample size formulas depend on –Study design –Outcome measure Dichotomous.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
Analyzing Randomized Control Trial: ITT vs. PP vs. AT Proceedings from Journal club….. Vikash.
Some terms Parametric data assumptions(more rigorous, so can make a better judgment) – Randomly drawn samples from normally distributed population – Homogenous.
1 HISTORY OF "CLINICAL TRIALS“ - 1, 1794 Treatment of yellow fever by bleeding, RUSH, 1794 “ I began to extract a small amount of blood each time. The.
Understanding real research 4. Randomised controlled trials.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
Design and Analysis of Clinical Study 2. Bias and Confounders Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
R Programming Risk & Relative Risk 1. Session 2 Overview 1.Risk 2.Relative Risk 3.Percent Increase/Decrease Risk 2.
1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
Literature Appraisal Effectiveness of Therapy. Measures of treatment effect Statistical significance Odds ratio Relative risk Absolute risk reduction.
1 Risk Assessment Tests Marina Kondratovich, Ph.D. OIVD/CDRH/FDA March 9, 2011 Molecular and Clinical Genetics Panel for Direct-to-Consumer (DTC) Genetic.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Survival Analysis 1 Always be contented, be grateful, be understanding and be compassionate.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Why we don’t like protocol violations Yuko Y. Palesch, PhD Medical University of South Carolina.
PTP 661 EVIDENCE ABOUT INTERVENTIONS CRITICALLY APPRAISE THE QUALITY AND APPLICABILITY OF AN INTERVENTION RESEARCH STUDY Min Huang, PT, PhD, NCS.
Sample Size Determination
Compliance Original Study Design Randomised Surgical care Medical care.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.
Session 6: Other Analysis Issues In this session, we consider various analysis issues that occur in practice: Incomplete Data: –Subjects drop-out, do not.
Garnet Anderson Katie Arnold SWOG Statistical Center Fred Hutchinson Cancer Research Center October 24, 2014.
Kenneth F. Schulz, PhD, MBA Triangle Global Health Consortium Breakfast Discussion.
Course: Research in Biomedicine and Health III Seminar 4: Critical assessment of evidence.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 6: Data and Analyses: Too Little or Too Much.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Medical Technology and Practice Patterns Institute 4733 Bethesda Ave., Suite #510 Bethesda, MD Phone: Fax: Comparison of.
CRITICAL APPARAISAL OF A PAPER ON THERAPY 421 CORSE EVIDENCE BASED MEDICINE (EBM)
CCEB STATISTICAL CONSIDERATIONS IN CLINICAL TRIALS Susan S. Ellenberg, Ph.D. University of Pennsylvania School of Medicine ASENT Clinical Trials Course.
Uses of Diagnostic Tests Screen (mammography for breast cancer) Diagnose (electrocardiogram for acute myocardial infarction) Grade (stage of cancer) Monitor.
1 臨床試驗 Statistical analysis (I) 統計分析 ( 一 ) 指標種類與選擇 簡國龍老師 【本著作除另有註明外,採取創用 CC 「姓名標示 -非商業性-相同方式分享」台灣 3.0 版授權釋出】創用 CC 「姓名標示 -非商業性-相同方式分享」台灣.
1 Statistical Issues in NDA Laura Lu, Ph.D FDA/CDER.
Methods to Handle Noncompliance
Trials Adrian Boyle.
Francis KL Chan Department of Medicine & Therapeutics CUHK
Martha Carvour, MD, PhD March 2, 2017
Interventional trials
Randomized Trials: A Brief Overview
NAPLEX preparation: Biostatistics
Comments on Methodological Challenges in Clinical Trials for CIPN Scott Evans, PhD, MS Harvard University ACTTION, 2017.
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Experimental Clinical Psychology Session V
Evidence Based Practice
Volume 375, Issue 9719, Pages (March 2010)
Yu Du, PhD Research Scientist Eli Lilly and Company
The Diabetic Retinopathy Clinical Research Network
Translating Data From Trial to Practice
Presentation transcript:

Analysis & Expressing Resultd in Clinical Trials Dr. Khalili

Type of Comparisons Dr. Khalili Trials to Show Superiority Trials to Show Eqivalance or Non-inferiority Trials to Show Dose-Response Relationship (Dose Finding Trials)

 Baseline Data Analysis  Outcome Data Analysis – Continious Data – Binary Data – Survival Data Analysis of results Dr. Khalili

Baseline Data Analysis To: – Check generalizability – Check comparability of treatment groups The variables should be considered: – The characteristics of the disease (type, severity, duration, …) – Prognostic variables – Other coincidence diseases – Previous treatments Use of statistical tests! Dr. Khalili

Outcom Analysis Continious Data:  Outcome analysis  Change score analysis  Analysis of Covariance (ANCOVA) Binary Data  Absolute Risk Difference (ARD)  Number needed to Treatment (NNT)  Risk Ratio (RR) or Odds Ratio (OR)  Adjusting for baseline covariates using logistic models Dr. Khalili

Protocol Deviation Patient ineligible Wrong treatment Competing events Noncompliance Loss to follow up Missing data Dr. Khalili

Protocol Deviation Approaches for analysis:  Intention to Treat  Per Protocol Adheres only As treated Dr. Khalili

Per-protocol Analysis A ‘per-protocol’ analysis excludes all patients who are known not to have completed the trial as planned.  Drop-outs  Non-compliers  Poor compliers  Falsely included Dr. Khalili

Intention to Treat An ‘intention to treat’ analysis actually analyses patients according to the treatment the trialist intended for them. Thus, a patient assigned to the active treatment, but who confessed to not taking it, would nevertheless be analyzed as if she had received the active treatment. Sometimes this is described as, ‘if randomized then analyzed’ Dr. Khalili

Intention to Treat (ITT) To keep randomization effective To evaluate effectiveness not efficacy Considered for pragmatic RCT Should be checked with the “Best” case and “worst” case analyses Decreases the power of study Dr. Khalili

Intention To Treat Vs Per-Protocol AA ABBBBA 1&2 Vs 3&4 Intention to Treat 1 Vs 2 Adheres only 1&4 Vs 2&3 As Treated Dr. Khalili

Some issues in multiple comparisons Multiple treatments Multiple outcomes Repeated measures Interim analyses Subgroups analyses Dr. Khalili

So much difficulty in research but we can do that. Dr. Khalili